Ascendis Pharma Europe A/S — Credit Rating and Financial Key Figures
CVR number: 44420449
Tuborg Boulevard 12, 2900 Hellerup
Income statement (kEUR)
2024 | |
|---|---|
| Fiscal period length | 12 |
| Net sales | |
| Gross profit | 27.00 |
| Costs of management | -32.00 |
| EBIT | -5.00 |
| Pre-tax profit | -5.00 |
| Net earnings | -5.00 |
Assets (kEUR)
2024 | |
|---|---|
| Intangible assets total | |
| Tangible assets total | |
| Other non-current investments | 26.00 |
| Investments total | 26.00 |
| Long term receivables total | |
| Inventories total | |
| Current amounts owed by group member comp. | 16.00 |
| Short term receivables total | 16.00 |
| Cash and bank deposits | 38.00 |
| Cash and cash equivalents | 38.00 |
| Balance sheet total (assets) | 80.00 |
Equity and liabilities (kEUR)
2024 | |
|---|---|
| Share capital | 54.00 |
| Profit of the financial year | -5.00 |
| Shareholders equity total | 49.00 |
| Non-current liabilities total | |
| Current owed to group member | 21.00 |
| Other non-interest bearing current liabilities | 10.00 |
| Current liabilities total | 31.00 |
| Balance sheet total (liabilities) | 80.00 |
CreditReports API
- Company information
- Financial data
- Credit risk data
- All 400,000+ Danish companies
Try the full version of our system for free
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions
... and more!
No registration needed.